

**RECEIVED**

NOV 09 2000

TECH CENTER 1800

Sheet 1 of 24

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## U. S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>SP</i>	3,940,422	02/24/1976	Harita et al.	260	340	01/17/74
	4,070,484	01/24/1978	Harita et al.	424	319	12/21/76
	4,093,709	06/06/1978	Sok Choi et al.	424	19	01/28/75
	4,389,330	06/21/1983	Tice et al.	427	213.36	10/06/80
	4,485,096	11/27/1984	Bell	424	95	05/26/82
	4,485,097	11/27/1984	Bell	424	95	05/25/83
	4,512,762	04/23/1985	Spears	604	21	11/23/82
	4,555,402	11/26/1985	Matsuda et al.	424	122	08/10/84
	4,577,636	03/25/1986	Spears	128	654	11/23/82
	4,664,097	05/12/1987	McGrath et al.	128	1 R	05/09/82
	4,675,189	06/23/1987	Kent et al.	424	490	02/08/85
	4,744,981	05/17/1988	Pavanasasivam	424	85	10/14/85
	4,824,436	04/25/1989	Wolinsky	604	53	04/21/87
	4,835,002	05/30/1989	Wolf et al.	426	590	07/10/87
	4,867,973	09/19/1989	Goers et al.	530	387	09/13/84
	4,879,225	11/07/1989	Morgan Jr. et al.	435	68	03/11/87
	4,897,255	01/30/1990	Fritzberg et al.	424	1	06/19/87
	4,906,452	03/06/1990	Sivam	424	10	04/28/88
	4,929,602	05/29/1990	Harker et al.	514	18	11/22/88
	4,935,415	06/19/1990	Nakano et al.	514	211	03/20/87
	4,962,091	10/09/1990	Eppstein et al.	514	2	05/23/96
	4,968,350	11/06/1990	Bindschaedler et al.	106	170	04/01/88
	4,994,033	02/19/1991	Shockey et al.	604	101	05/29/89
	5,009,659	04/23/1991	Hamlin et al.	606	159	10/30/89
	5,015,578	05/14/1991	Schroeder et al.	435	119	02/20/90
	5,026,537	06/25/1991	Daddona et al.	424	1.1	05/06/89
	5,032,679	07/16/1991	Brandley et al.	536	21	08/31/89
	5,043,335	08/27/1991	Kleinschroth et al.	514	211	06/23/90
	5,049,132	09/17/1991	Schaffer et al.	604	101	01/08/90
	5,053,033	10/01/1991	Clarke et al.	606	3	10/10/90
	5,059,166	10/22/1991	Fischell et al.	600	3	12/11/89
	5,066,789	11/19/1991	Srinivasan et al.	530	388	09/29/89
	5,073,633	12/17/1991	Schroeder et al.	540	545	11/05/90
	5,093,330	03/03/1992	Caravatti et al.	514	211	03/21/91
	5,099,504	05/28/1991	Christen et al.	435	123	03/23/89
	5,102,402	04/07/1992	Dror et al.	604	265	01/04/91
	5,112,305	05/12/1992	Barath et al.	704	96	10/16/90
	5,114,719	05/19/1992	Sabel et al.	424	422	09/14/89

Examiner <i>SP</i>	Date Considered <i>8/27/01</i>
--------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>SL</i>	5,114,847	05/19/1992	Jungfer et al.	435	41	04/29/83
	5,116,864	05/26/1992	March et al.	514	455	04/09/91
	5,140,012	08/18/1992	McGovern et al.	514	19	05/31/90
	5,166,143	11/24/1992	Ondetti et al.	514	89	06/13/91
	5,171,217	12/15/1992	March et al.	604	53	02/28/91
	5,176,617	01/05/1993	Fischell et al.	600	3	11/21/91
	5,180,366	01/19/1993	Woods	604	96	10/10/90
	5,185,260	02/09/1993	Crissman et al.	435	244	08/29/91
	5,199,939	04/06/1993	Dake et al.	600	3	02/23/90
	5,208,019	05/05/1993	Hanson et al.	424	85	09/27/89
	5,208,238	05/04/1993	King	514	255	06/18/90
	5,213,576	05/25/1993	Abiuso et al.	604	96	06/11/91
	5,213,580	05/25/1993	Slepian et al.	623	1	03/25/92
	5,216,024	06/01/1993	Markaverich et al.	514	543	07/15/88
	5,226,430	07/13/1993	Spears et al.	128	898	05/24/91
	5,232,911	08/03/1993	Vidal	514	12	07/23/91
	5,238,950	08/24/1993	Clader et al.	514	360	12/17/91
	5,242,397	09/07/1993	Barath et al.	604	96	01/02/92
	5,248,764	09/28/1993	Flanagan et al.	530	324	02/27/92
	5,260,224	11/09/1993	Stossel et al.	436	503	10/10/91
	5,268,358	12/07/1993	Fretto et al.	514	12	05/06/91
	5,270,047	12/14/1993	Kauffman et al.	424	422	11/21/91
	5,280,016	01/18/1994	Conrad et al.	514	56	09/03/91
	5,282,785	02/01/1994	Shapland et al.	604	21	10/05/92
	5,283,257	02/01/1994	Gregory et al.	514	458	07/10/92
	5,284,869	02/08/1994	Bisaccia et al.	514	455	12/17/91
	5,288,711	02/22/1994	Mitchell et al.	514	56	04/28/92
	5,288,735	02/22/1994	Trager et al.	514	363	06/15/92
	5,296,492	03/22/1994	Shiozawa et al.	514	337	06/03/92
	5,304,325	04/19/1994	Kaufman et al.	252	312	11/13/91
	5,308,622	05/03/1994	Casscells et al.	424	422	07/16/92
	5,308,862	05/03/1994	Ohlstein et al.	514	411	03/05/93
	5,314,679	05/24/1994	Lewis et al.	424	9	12/22/92
	5,316,766	05/31/1994	Baldus et al.	424	94	02/06/90
	5,324,739	06/28/1994	Gerwick et al.	514	365	10/07/93
	5,326,757	07/05/1994	Demopoulos	514	167	08/18/93
	5,328,471	07/12/1994	Slepian	604	101	08/04/93
<i>SL</i>	5,332,584	07/26/1994	Scher et al.	424	408	12/09/91

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>SLB</i>	5,342,926	08/30/1994	Hattner	534	10	06/08/93
	5,344,926	09/06/1994	Murakata et al.	540	545	06/22/93
	5,346,702	09/13/1994	Na et al.	424	490	12/04/92
	5,346,897	09/13/1994	King	514	290	06/10/92
	5,346,993	09/13/1994	Miyazono et al.	530	399	07/15/93
	5,354,562	10/11/1994	Platz et al.	424	489	01/16/93
	5,354,774	10/11/1994	Deckelbaum et al.	514	455	12/24/92
	5,354,801	10/11/1994	O'Toole et al.	524	461	08/12/93
	5,356,713	10/18/1994	Charmot et al.	428	407	06/01/93
	5,358,844	10/25/1994	Stossel et al.	435	2	02/18/93
	5,362,424	11/08/1994	Lee, H., et al.	264	4.3	10/10/91
	5,364,632	11/15/1994	Benita, S., et al.	424	450	03/09/93
	5,364,843	11/15/1994	King, A.C.	514	15	06/10/92
	5,380,716	01/10/1995	Conrad, H.E., et al.	514	56	12/28/92
	5,385,935	01/31/1995	Tamai, H., et al.	514	535	09/07/93
	5,393,772	02/28/1995	Yue, T.Y., et al.	514	410	11/24/93
	5,395,610	03/07/1995	King, A.C.	424	10	05/28/93
	5,407,609	04/18/1995	Tice, T.R., et al.	264	46	05/17/93
	5,407,658	04/18/1995	Hattner, R.S.	424	1.65	05/24/94
	5,423,885	06/13/1995	Williams, M.S.	623	1	07/14/93
	5,429,634	07/04/1995	Narcisco Jr., H.L.	604	890.1	09/09/93
	5,441,947	08/15/1995	Dodge, J.A., et al.	514	179	08/25/93
	5,453,436	09/26/1995	Ohlstein, E.H.	514	411	03/17/94
	5,453,442	09/26/1995	Bryant, H.U., et al.	514	408	02/18/94
	5,460,807	10/24/1995	Cardin, A.D., et al.	424	78	08/19/92
	5,468,746	11/21/1995	Casagrande, C., et al.	514	235.5	06/21/91
	5,478,860	12/26/1995	Wheeler, J.J., et al.	514	449	06/04/93
	5,498,775	03/12/1996	Novak, S.T., et al.	514	25	11/07/94
	5,516,781	05/14/1996	Morris, R.E., et al.	514	291	05/12/94
	5,516,807	05/14/1996	Hupe, D., et al.	514	673	10/25/94
	5,519,042	05/21/1996	Morris, R.E., et al.	514	378	01/13/94
	5,521,191	05/28/1996	Greenwald, J.E.	514	262	10/17/94
	5,527,337	06/18/1996	Stack et al.	606	198	02/01/91
	5,576,345	11/19/1996	Mansson et al.	514	449	11/10/94
	5,580,898	12/03/1996	Trojanowski et al.	514	449	05/24/94
	5,583,153	12/10/1996	Brahn	514	449	10/06/94
	5,616,608	04/01/1997	Kinsella, J.L., et al.	514	449	04/18/96
<i>SLB</i>	5,660,873	08/26/1997	Nikolaychik et al.	427	2.24	09/09/94

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449\*

Atty. Docket No.: 295.007US4

Serial No. 09/590,002

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicant: Lawrence L. Kunz

Filing Date: June 8, 2000

Group: 1614

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<u>549</u>	5,716,981	02/10/1998	Hunter, W.L., et al.	514	449	06/07/95
	5,733,925	03/31/1998	Kunz, L., et al.	514	499	10/28/96
	5,847,007	12/08/1998	Grainger, D.J., et al.	514	651	05/12/94
	Re. 32,944	06/06/1989	Harita, K., et al.	562	455	06/01/77
<u>83</u>	Re. 33,403	10/1/23/1990	Stolle, R.J., et al.	424	87	01/13/89

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes   No
<u>549</u>	0 297 946	01/04/1989	European	A61K	31/40	
	0 365 863	05/02/1990	European			
	0 411 893	02/06/1991	European	C12N	15/13	
	0 451 202	10/16/1991	European			
	0 524 093	01/20/1993	European	C07D	305/14	
	0 526 102	02/03/1993	European	A61M	29/02	
	0 577 215	01/05/1993	European			
	0 588 518	02/23/1994	European			
	0 606 613	07/20/1994	European	G01N	33/531	
	0 622 076	11/02/1994	European			
	0 639 577	02/22/1995	European	C07F	9/655	
	0 691 130	01/10/1996	European	A61K	31/71	
	88/10259	12/29/1988	PCT	C07D	313/00	
	90/01969	03/08/1990	PCT			
	90/11676	10/18/1990	PCT			
	90/13293	11/15/1990	PCT	A61K	31/40	
	91/15219	10/14/1991	PCT			
	92/11890	07/23/1992	PCT	A61M	25/00	
	92/11895	07/23/1992	PCT	A61K	31/00	
	92/18546	10/29/1992	PCT	C08B	37/10	
	92/19273	11/12/1992	PCT			
	92/21363	12/10/1992	PCT			
	93/02065	02/04/1993	PCT	C07D	305/14	
	93/07748	04/29/1993	PCT			
	93/09790	05/27/1993	PCT			
	93/11120	06/10/1993	PCT	C07D	263/62	
	93/17121	09/02/1993	PCT	C12P	17/02	
	93/24476	12/09/1993	PCT	C07D	305/14	
<u>83</u>	94/03644	02/17/1994	PCT	C12Q	1/68	

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
SP	94/04164	03/03/1994	PCT	A61K	31/795		
	94/04178	03/03/1994	PCT				
	94/07529	04/14/1994	PCT	A61K	39/00		
	94/08604	04/28/1994	PCT	A61K	37/00		
	94/08605	04/28/1994	PCT	A61K	37/00		
	94/15589	07/21/1994	PCT	A61K	9/50		
	94/15590	07/21/1994	PCT	A61K	9/51		
	94/15646	07/21/1994	PCT	A61K	48/00		
	94/16706	08/04/1994	PCT				
	94/17786	08/18/1994	PCT	A61K	9/16		
	94/18345	08/18/1994	PCT	C12Q	1/68		
	94/18954	09/01/1994	PCT	A61K	9/48		
	94/18967	09/01/1994	PCT	A61K	31/415		
	94/18968	09/01/1994	PCT	A61K	31/415		
	94/19000	09/01/1994	PCT	A61K	37/02		
	94/19001	09/01/1994	PCT	A61K	37/02		
	94/19003	09/01/1994	PCT	A61K	37/02		
	94/20096	09/15/1994	PCT	A61K	31/40		
	94/20097	09/15/1994	PCT	A61K	31/40		
	94/21679	09/29/1994	PCT	C07K	13/00		
	94/22436	10/13/1994	PCT				
	94/23699	10/27/1994	PCT	A61K	9/14		
	94/25020	11/10/1994	PCT	A61K	31/335		
	94/25053	11/10/1994	PCT	A61K	37/02		
	94/26291	11/24/1994	PCT	A61K	37/02		
	94/26303	11/24/1994	PCT	A61K	39/00		
	94/27612	12/08/1994	PCT				
	94/28721	12/22/1994	PCT	A01N	43/42		
	95/03036	02/02/1995	PCT				
	95/03795	02/09/1995	PCT	A61K	31/335		
	95/20582	08/03/1995	PCT	C07D	305/14		
SP	95/33736	12/14/1995	PCT	C07D	305/14		
	96/20698	07/11/1996	PCT	A61K	9/51		

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
------------------	--

Examiner <u>SP</u>	Date Considered <u>8/27/01</u>
--------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SR	"Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part I", <u>Drug &amp; Market Development</u> , 5, 121-129, (Sep. 26, 1994).
	"Cytochalasins", <u>Merck Index</u> , Eleventh Edition, p. 438 (1989).
	"Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", <u>Circulation</u> , 90, I-82, Abstract No. 3509, (October 1988).
	Allemann et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoxepoine Loaded Poly (D,L-lactic acid) Nanospheres to Rats", <u>J. Controlled Release</u> , 29, 97-104 (1994).
	Allemann et al., "Drug Loaded Poly(lactic acid) Nanoparticles Produced by a Versible Salting-out Process: Purification of an Injectable Dosage Form", <u>Eur. J. Pharm. Biopharm.</u> , 39, 13-18 (1993).
	Attwood et al., "A Light Scattering Study on Oil-in-Water Microemulsions", <u>Int'l J. Pharm.</u> , 52, 165-171 (1989).
	Bamburg et al., "Biological and Biochemical Actions of Trichothecene Mycotoxins", In: <u>Progress in Molecular and Subcellular Biology</u> , 8, Hahn, F.E., et al., (eds.), Springer-Verlag, New York, p. 41-110, (1983).
	Barath et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", <u>JACC</u> , 13, 252A (February 1989).
	Barbacid et al., "Binding of [acetyl-14C]Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes", <u>Euro. J. Biochem.</u> , 44, 437-444, (1974).
	Barinaga, "Gene Therapy for Clogged Arteries Passes to Test in Pigs", <u>Science</u> , 265, 738 (5 August 1994).
SR	Beck et al., "Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectible biodegradable contraceptive", <u>Biol. Reprod.</u> , 28, 186-195 (1983).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SA	Benita et al., "Submicron Emulsions as Colloidal Drug Carriers for Intravenous Administration: Comprehensive Physicochemical Characterization", <u>J. of Pharmaceutical Sciences</u> , 82, 1069-1079 (1993).
	Bier et al., "Arterial Remodeling: Importance in Primary Versus Restenotic Lesions", <u>JACC</u> , Abstract No. 875-96, p. 139A, (Feb. 1994).
	Bogyo et al., "Cytochalasin-B-induced Immunosuppression of Murine Allogenic Anti-Tumor Response and the Effect of Recombinant Human Interleukin-2", <u>Cancer Immunol. Immunother.</u> , 32, 400-405 (1991).
	Bousquet et al., "Effects of Cytochalasin B in Culture In Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma", <u>Cancer Research</u> , 50, 1431-1439 (1990).
	Brott, et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", <u>JACC</u> , Abstract No. 875-43, p. 138A, (Feb., 1994).
	Bumol et al., "Unique Glycoprotein-proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells", <u>PNAS USA</u> , 79, 1245-1249 (1982).
	Camenzind et al., "Use of Locally Delivered Conventional Drug Therapies", <u>Semin. Intervent. Cardiol.</u> , 1, 67-76 (1996).
	Cannon et al., "Competition Between Trichodermin and Several Other Sesquiterpene Antibiotics for Binding to their Receptor Site(s) on Eukaryotic Ribosomes", <u>Biochem. J.</u> , 160, 137-145 (1976).
	Chaldakov et al., "Cyclic AMP- and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization", <u>Cell and Tissue Research</u> , 255, 434-442 (1989).
	Chang et al., "Comparison of the Intoxication Pathways of Tumor Necrosis Factor and Diphtheria Toxin", <u>Infection and Immunity</u> , 58, 2644-2650 (1990).
SA	Chapman et al., "A Bioabsorbable Stent: Initial Experimental Results", <u>Supplement III Circulation</u> , 82, p. III-72, Abstract No.0283 (October 1990).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

54 Chauhan et al., "Activation of Transforming Growth Factor-beta is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(a), LDL-Cholesterol and Plasminogen Activator Inhibitor-1", Circulation, 90, 67th Scientific Sessions, Abstract No. 3354, p. I-623, (Oct., 1994).

Clowes et al., "Kinetics of Cellular Proliferation after Arterial Injury -- I. Smooth Muscle Growth in the Absence of Endothelium", Laboratory Investigation, 49, 327-333 (1983).

Clowes et al., "Kinetics of Cellular Proliferation after Arterial Injury -- III. Endothelium and Smooth Muscle Growth in Chronically Denuded Vessels", Laboratory Investigation, 54, 295-303 (1986).

Clowes et al., "Mechanisms of Stenosis after Arterial Injury", Laboratory Investigation, 49, 208-215 (1983).

Clowes et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", Circulation Research, 56, 139-145 (1985).

Cohen et al., "Controlled Delivery Systems for Proteins Based on Poly(lactic/glycolic acid) Microspheres", Pharmaceutical Research, 8, 713-720 (1991).

Cole et al., "The Cytochalasins", In: Handbook of Toxic Fungal Metabolites, Academic Press, New York, p. 264-265, 281-282 (1981).

Cotton, "Restenosis Trials Suggest Role for Remodeling", JAMA, 271, 1302-1305 (1994).

Cowsar et al., "Poly(actide-co-glycolide) Microcapsules for Controlled Release of Steroids", Methods Enzymology, 112, 101-116 (1985).

Craig et al., "Anticoagulant Drugs", in Modern Pharmacology, Little, Brown & Co., Boston, p. 399 (1982).

Crissman et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G1 Phase of the Cell Cycle", Proc. Natl. Acad. Sci. USA, 88, 7580-7584 (1991).

Examiner

S/B

Date Considered

8/27/01

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

543	Currier et al., "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?", <u>JACC</u> , 25, 516-520 (1995).
	Detre et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", <u>The New England Journal of Medicine</u> , 318, 265-270 (1988).
	Di Mario et al., "Is the Mechanism of Restenosis Device-Independent? Serial Assessment with Intracoronary Ultrasound", <u>Circulation</u> , 90, Abstract No. 115, p. I-24, (1994).
	Eldridge et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies", <u>Infection and Immunity</u> , 59, 2978-2986 (1991).
	Epstein et al., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells", <u>Circulation</u> , 84, 778-787 (1991).
	Fanelli et al., "Restenosis Following Coronary Angioplasty", <u>American Heart Journal</u> , 119, 357-368 (1990).
	Faxon et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", <u>Arteriosclerosis</u> , 4, 189-195 (1984).
	Fay et al., "Effects of Cytochalasin B on the Uptake of Ascorbic Acid and Glucose by 3T3 Fibroblasts: Mechanism of Impaired Ascorbate Transport in Diabetes", <u>Life Sciences</u> , 46, 619-624 (1990).
	Fischell, T.A., et al., "Low-Dose, Beta-Particle Emission From 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation", <u>Circulation</u> , 90, 2956-2963 (1994).
	Fischman, D.L., et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", <u>The New England Journal of Medicine</u> , 331, 496-501 (1994).
5B	Forrester et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", <u>JACC</u> , 17, 758-769 (1991).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>SL</i>	Friberg et al., "Microemulsions and Solubilization by Nonionic Surfactants", <u>Prog. Colloid and Polymer Sci.</u> , 56, 16-20 (1975).
	Fulop et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes under Various Stimuli", <u>Immunobiol.</u> , 171, 302-310 (1986).
	Garrigues et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface.", <u>J. Cell. Biol.</u> , 103, 1699-1710 (1986).
	Gasco et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", <u>International Journal of Pharmaceutics</u> , 62, 193-196 (1991).
	Gasco et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection", <u>Intl. J. of Pharmaceut.</u> , 62, 119-123 (1990).
	Gertz et al., "Geometric Remodeling Is Not the Principal Pathogenic Process in Restenosis After Balloon Angioplasty", <u>Circulation</u> , 90, 3001-3009 (1994).
	Gibbons et al., "The Emerging Concept of Vascular Remodeling", <u>New England Journal of Medicine</u> , 330, 1431-1438 (1994).
	Glagov, "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", <u>Circulation</u> , 89, 2888-2891 (1994).
	Glagov et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries", <u>New England Journal of Medicine</u> , 316, 1371-1375 (1987).
	Goldman et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase", <u>Atherosclerosis</u> , 65, 215-225, (1987).
	Grainger et al., "A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells.", <u>Biochemical Journal</u> , 277, 145-151 (1991).
<i>SL</i>	Grainger et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", <u>Circulation</u> , 90, 67th Scientific Session, Abstract No. 3353, p. I-623, (Oct., 1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449\*

Atty. Docket No.: 295.007US4

Serial No. 09/590,002

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicant: Lawrence L. Kunz

(Use several sheets if necessary)

Filing Date: June 8, 2000

Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

5/13 Grainger et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein(a) Mice", Nature, 370, 460-462 (1994).

Grainger et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chemica Acta, 235, 11-31 (1995).

Grainger et al., "Active TGF-beta is Depressed Five-Fold in Triple Vessel Disease Patients Compared with Syndrome X Patients", Journal of Cellular Biochemistry, 18A, Abstract No. E111, p. 267 (1994).

Grainger et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", Circulation, 90, 67th Scientific Sessions, Abstract No. 2754, p. I-512 (1994).

Grainger et al., "Heparin Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Releasing Transforming Growth Factor beta-like Activity from Serum", Cardiovascular Research, 27, 2238-2247 (1993).

Grainger et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", Biochemical Journal, 283, 403-408 (1992).

Grainger et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Serum-Free Primary Culture", Cardiovascular Research, 28, 1238-1242 (1994).

Grainger et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", Science, 260, 1655-1658 (1993).

Grainger et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth-Muscle Cells in Culture by Inducing Production of Transforming Growth Factor Beta", Biochem. J., 294, 109-112 (1993).

Grainger et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severely Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80 (1995).

5/13 Grainger et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Delays the Rise in Cyclic AMP Before Entry into M Phase", Biochemical Journal, 299, 227-235 (1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

5/	Grainger et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", <u>Current Opinion In Lipidology</u> , 6, 81-85 (1995).
	Gref et al., "Biodegradable Long-Circulating Polymeric Nanoshoores.", <u>Science</u> , 263, 1600-1603 (1994).
	Hanke et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", <u>Circulation</u> , 85, 1548-1556 (1992).
	Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", <u>Circulation</u> , 92, 1570-1575 (1995).
	Heller et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols", <u>J. Polymer Science</u> , Polymer Letters Edition, 18, 293-297 (April 1980).
	Henriksson et al., "Hormonal Regulation of Serum Lp (a) Levels.", <u>J. Clin. Invest.</u> , 89, 1166-1171 (1992).
	Hoff et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages", <u>Arteriosclerosis</u> , 9, 538-549 (July/Aug. 1989).
	Hofmann et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", <u>Int. J. Cancer</u> , 42, 382-388 (1988).
	Holland et al., "Atherogenic Levels of Low-Density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells", <u>American Journal of Pathology</u> , 140, 551-558 (1992).
	Holmes, Jr., "Remodeling Versus Smooth Muscle Cell Hyperplasia", <u>Restenosis Summit VI</u> , The Cleveland Clinic Foundation, 222-223 (1994).
	Huehns et al., "Adventitia as a Target for Intravascular Local Drug Delivery", <u>Heart</u> , 75, 537-538 (1996).
5/	Isner, "Vascular Remodeling: Honey, I Think I Shrunk the Artery", <u>Circulation</u> , 89, 2937-2841 (1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SA	Jande et al., "Effects of Cytochalasin B and Dihydrocytochalasin B on Calcium Transport by Intestinal Absorptive Cells", <u>Calcified Tissue International</u> , 33, 143-151 (1981).
	Jarvis et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica", In: <u>Chemistry of Allelopathy: Biochemical Interactions Among Plants</u> , ACS Symposium Series No. 268, Thompson, A.C., (ed.), 149-159 (1985).
	Jarvis et al., "Macrocyclic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance", <u>Acc. Chem. Res.</u> , 15, 388-395 (1982).
	Jenkins et al., "Local Delivery of Taxol Inhibits Neointimal Regrowth Following Balloon Injury of the Rat Carotid Artery", <u>Circulation</u> , 90, 67th Scientific Sessions, Abstract No. 1596, p. I-297 (1994).
	Johnson et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues", <u>Supp. II Circulation</u> , 78, Abstract No. 0327, page 11-82 (1988).
	Jung et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions", <u>Thrombosis Research</u> , 50, 775-787 (1988).
	Kakuta et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", <u>Circulation</u> , 89, 2809-2815 (1994).
	Kakuta et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", <u>JACC</u> , Abstract No. 875-95, p. 138A, (Feb., 1994).
	Kambic et al., "Biomaterials in Artificial Organs", <u>Chem. Eng. News</u> , 30, 31-48 (1986).
3AB	Kemp, P.R., et al., "Cloning and Analysis of the Promoter Region of the Rat SM22-Alpha Gene", <u>Biochem. J.</u> , 310, 1037-1043 (1995).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>SB</i>	Kemp et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle Cells by the Expression of a Truncated PDGF Receptor", <u>FEBS Letters</u> , 336, 119-123 (1993).
	Kemp et al., "The Id Gene is Activated by Serum but is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells", <u>Biochemical Journal</u> , 277, 285-288 (1991).
	Kingston et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives as Anticancer Agents", In: <u>New Trends in Natural Products Chemistry</u> , Studies in Organic Chemistry, Vol. 26, Rahman, Atta-ur-, et al., (eds), pp. 219-235 (1986).
	Kirschenlohr et al., "Adult Human Aortic Smooth Muscle Cells in Culture Produce Active TFG-Beta", <u>Amer. J. Physiol.</u> , 265, C571-C576 (1993).
	Kirschenlohr et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", <u>Cardiovascular Research</u> , 29, 848-855 (1995).
	Kovach et al., "Serial Intravascular Ultrasound Studies Indicate that Chronic Recoil is an Important Mechanism of Restenosis Following Transcatheter Therapy", <u>JAAC</u> , 21, Abstract No. 835-3, p. 484A (1993).
	Kreuzer et al., "Lipoprotein(a) Displays Increased Accumulation Compared with Low-Density Lipoprotein in the Murine Arterial Wall", <u>Chemistry and Physics of Lipids</u> , 67/68, 175-190 (1990).
	Kunert et al., "Paclitaxel Inhibits Development of Restenosis Following Experimental Balloon Angioplasty in the Rabbit Carotid Artery", <u>European Heart Journal</u> , 17, 368 (1996).
	Kuntz et al., "Defining Coronary Restenosis -- Newer Clinical and Angiographic Paradigms", <u>Circulation</u> , 88, 1310-1323 (1993).
<i>SB</i>	Kunz et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", <u>Journal of the American College of Cardiology</u> , Supplement A, Abstract No. 984-23, p. 302, (Mar. 1995).

Examiner

*HB*

Date Considered

*8/27/01*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*9*

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>JK</i>	Kunz et al., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of Geometric Remodeling in Restenosis", <u>JACC</u> , 44th Annual Scientific Session, Abstract No. 122292, 1 p. (Mar. 19-22, 1995).
	Kunz et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Artery Injury Model", <u>Circulation</u> , 90, 67th Scientific Sessions, Abstract No. 1598, p. I-297 (Oct., 1994).
	Labhsetwar, "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries", <u>Proc. Intern. Symp. Control. Rel. Bioact. Mater.</u> , 22, 182-183 (1995).
	Lafont et al., "Post-Angioplasty Restenosis in the Atherosclerotic Rabbit: Proliferative Response or Chronic Constriction?", <u>Circulation</u> , 88, 66th Scientific Sessions, Abstract No. 2806, p. I-521 (1993).
	Lambert et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs", <u>Coronary Artery Disease</u> , 4, 469-475 (1993).
	Langbein, "Too Many Drugs, Too Little Value in CV Conditions", <u>In Vivo. The Business and Medicine Report</u> , 14-20 (1995).
	Leroux et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", <u>Eur. J. Pharm. Biopharm.</u> , 41, 14-18 (1995).
	Leroux et al., "Interanalization of poly(D L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles", <u>J. Biomed. Mater. Res.</u> , 28, 471-481 (1994).
	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", <u>Intl. J. Pharmaceut.</u> , 66, 29-37 (1990).
	Levy et al., "Strategies for Treating Arterial Restenosis using Polymeric Controlled Release Implants", <u>Chemical Abstracts</u> , 121, Abstract No. 263625g, p. 580 (1994).
<i>JK</i>	Li et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", <u>Biochimica et Biophysica Acta</u> , 1042, 42-50 (1990).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SB	Liaw et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and is Chemotactic for Smooth Muscle Cells <i>In Vitro</i> ", <u>Cir. Res.</u> , 74, 214-224 (1992).
	Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis", <u>Circulation</u> , 90, 2070-2084 (1994).
	Linn et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", <u>Drug Development and Industrial Pharmacy</u> , 16, 899-920 (1990).
	Lipski et al., "Cytochalasin B: Preparation, Analysis in Tissue Extracts, and Pharmacokinetics after Intraperitoneal Bolus Administration in Mice", <u>Analytical Biochemistry</u> , 161, 332-340 (1987).
	Liu et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia", <u>Circulation</u> , 79, 1374-87 (1989).
	Luo et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty: An Intravascular Ultrasound Analysis", <u>Circulation</u> , 90, 67 Scientific Sessions, Abstract No. 0318, p. I-61 (1994).
	Macander et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy", <u>Catheterization and Cardiovascular Diagnosis</u> , 37, 125-131 (1990).
	Malcolmson et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", <u>J. Pharm. Pharmacol.</u> , 42, 6P (1990).
	Manasek et al., "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B", <u>Proc. Natl. Acad. Sci. USA</u> , 69, 308-213 (1972).
	Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", <u>Science</u> , 265, 320 (1994).
SA	Marzocchi et al., "Restenosis After Coronary Angioplasty: Its Pathogenesis and Prevention", <u>Cardiologia</u> , 36, Translation, 11 p., 309-320 (1991).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.007US4

Serial No. 09/590,002

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicant: Lawrence L. Kunz

Filing Date: June 8, 2000

Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SB McCaffrey et al., "Transforming Growth Factor-beta Activity is Potentiated by Heparin via Dissociation of the Transforming Growth Factor-beta/alpha2-Macroglobulin Inactive Complex", The Journal of Cell Biology, 109, 441-448 (1989).

McLaughlin et al., "Inhibition of Protein Synthesis by Trichothecenes", In: Mycotoxins in Human and Animal Health, Pathotox Publishers, Inc., 263-273 (1977).

McQuiggan, "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on beta-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells", Masters' Thesis, Syracuse University, New York, 41 p., (Dec., 1988)

Metcalfe et al., "Protein Markers of Lesion Development in the Vessels of Transgenic Apo(a) Mice", Journal of Cellular Biochemistry, Supplement 18A, Abstract No. E212, p. 280 (1994).

Metcalfe et al., "Transforming Growth Factor-beta and the Protection From Cardiovascular Injury Hypothesis", Biochemical Society Transactions, 23, 403-406 (1995).

Meyer, "Functionalized Cytochalasins for Potential Biotechnology Transfer", Ph. D. Thesis (Selected Pages), Syracuse University, New York, 13 p., (May, 1994).

Middlebrook et al., "Binding of T-2 Toxin to Eukaryotic Cell Ribosomes", Biochemical Pharmacology, 38, 3103-3110 (1989).

Middlebrook et al., "Specific Association of T-2 Toxin with Mammalian Cells", Biochemical Pharmacology, 38, 3093-3102 (1989).

Mintz et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascular Ultrasound Study", JACC, Abstract No. 875-97, p. 138A (Feb. 1994).

SA Mintz et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Coronary Angioplasty", JACC, Abstract No. 875-42, p. 138A, (Feb. 1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

S/S	Mintz et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", <u>Circulation</u> , 90, Abstract No. 117, p. I-24 (1994).
	More et al., "A Targeted Antithrombotic Conjugate with Antiplatelet and Fibrinolytic Properties which Reduces <i>in vivo</i> Thrombus Formation", <u>Cardiovascular Research</u> , 27, 2200-2204 (1993).
	Morisaki et al., "Effects of Transforming growth factor- $\beta$ on Growth of Aortic Smooth Muscle Cells", <u>Atherosclerosis</u> , 88, 227-234 (1991).
	Mosedale et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differentiation <i>In Vivo</i> ", <u>Circulation</u> , 90, 67th Scientific Session, Abstract No. 1590, p. I-296 (1994).
	Mueller et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", <u>Bioconjugate Chem.</u> , 1, 325-330 (1990).
	Nabel, "Recombinant Gene Expression <i>In Vivo</i> Within Endothelial Cells of the Arterial Wall", <u>Science</u> , 244, 1342-1344 (1989).
	Nabel et al., "Direct Transfer of Transforming Growth Factor Beta-1 Group Into Arteries Stimulates Fibrocellular Hyperplasia", <u>Proc. Natl. Acad. Sci. USA</u> , 90, 10759-10763 (1993).
	Naito et al., "Vascular Endothelial Cell Migration <i>In Vitro</i> : Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System", <u>Artery</u> , 17, 21-31 (1989).
	Nakao et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid", <u>Atherosclerosis</u> , 46, 309-319 (1983).
	Navarro et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", <u>USB Securities, Equity Research -- Medical Technology</u> , 10 p., (Mar. 3, 1995).
S/S	Nunes et al., "Vitamins C and E Improve the Response to Coronary Balloon Injury in the Pig: Effect of Vascular Remodeling", <u>Circulation</u> , 88, Abstract No. 1994, p. I-372 (1993).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

5/3	O'Brien et al., "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification.", <u>Circulation</u> , 88, Abstract No. 3330, I-609 (1993).
	Ohmi et al., "Effect of K252a, A Protein Kinase Inhibitor, on the Proliferation of Vascular Smooth Muscle Cells", <u>Biochemical and Biophysical Research Communications</u> , 173, 976-981 (1990).
	Ohno et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Arterial Injury", <u>Science</u> , 265, 781-784 (1994).
	Oliveira et al., "Isolation and Characterization of Smooth Muscle Cell Membranes", <u>Biochimica et Biophysica Acta</u> , 332, 221-232 (1974).
	Orlov et al., "Altered Beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Muscle Cells From the Aorta of Spontaneously Hypertensive Rats", <u>American Journal of Hypertension</u> , 8, 739-747 (1995).
	Osborne et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Transdermal Studies of a Model Hydrophilic Drug", <u>J. Pharm. Pharmacol.</u> , 43, 450-454 (1991).
	Osipow, "Transparent Emulsion", <u>J. Soc. Cosmetic Chemists</u> , 277-285 (1963).
	Palmaz et al., "Intravascular Stents", In : <u>Advances in Vascular Surgery</u> , Vol. 1, Mosby-Year Book Inc., pp 107-135 (1993).
	Pardee et al., "Control of Cell Proliferation", <u>Cancer</u> , 39, 2747-2754 (1977).
	Pathak et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", <u>International Journal of Pharmaceutics</u> , 65, 169-175 (1990).
	Podzimek et al., "O/W Microemulsions", <u>J. Dispersion Science and Technology</u> , I, 341-359 (1980).
	Popma et al., "Factors Influencing Restenosis after Coronary Angioplasty", <u>The American Journal of Medicine</u> , 88, 1-16N--1-24N (1990).
8/3	Post et al., "Restenosis is Partly Due to Intimal Hyperplasia and Partly to Remodeling of the Injured Arterial Wall", <u>European Heart Journal</u> , Abstract No. P1164, p. 201 (1993).

Examiner <u>ELB</u>	Date Considered <u>8/27/01</u>
---------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

33	Post et al., "The Relative Importance of Arterial Remodeling Compared with Intimal Hyperplasia in Lumen Renarrowing After Balloon Angioplasty", <u>Circulation</u> , <u>89</u> , 2816-2821 (1994).
	Post et al., "Which Part of the Angiographic Diameter Reduction After Balloon Dilation is Due to Intimal Hyperplasia?", <u>JACC</u> , <u>21</u> , Abstract No. 851-95, I-36A (1993).
	Pouton, "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", <u>International Journal of Pharmaceutics</u> , <u>27</u> , 335-348 (1985).
	Rauterberg et al., "Collagens in Atherosclerotic Vessel Wall Lesions", <u>Current Topics in Pathology</u> , <u>87</u> , 163-192 (1993).
	Reid et al., "Fragmentation of DNA in P388D, Macrophages Exposed to Oxidized Low-Density Lipoprotein", <u>FEBS Letters</u> , <u>332</u> , 218-220 (1993).
	Riessen et al., "Regional Differences in the Distribution of the Proteglycans Biglycan and Decorin in the Extracellular Matrix of Atherosclerotic and Restenotic Human Coronary Arteries", <u>Amer. J. Path.</u> , <u>144</u> , 962-974 (1994).
	Riessen et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", <u>Journal of the American College of Cardiology</u> , <u>23</u> , 1234-1244 (1994).
	Ross, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <u>Nature</u> , <u>362</u> , 801-809 (1993).
	Rutsch et al., "Benestent-II Pilot Study: 6 Months Follow Up of Phase 1", <u>Abstract, Society of Cardiology</u> , (1995).
	Sagitani et al., "Microemulsion Systems with a Nonionic Cosurfant", <u>J. Dispersion Science and Technology</u> , <u>1</u> , 151-164 (1980).
	Sanders et al., "Controlled Release of a Lutenizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres", <u>J. Pharmaceutical Science</u> , <u>73</u> , 1294-1297 (1984).
54	Sanderson et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", <u>Circulation</u> , <u>90</u> , Abstract No. 2734, p. I-508, (1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SB	Schatz et al., "A View of Vascular Stents", <u>Circulation</u> , 79, 445-457 (1989).
	Schlingemann et al., "Expression of the High Molecular Weight Molenoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds", <u>Amer. J. Pathology</u> , 136, 1393-1405 (1990).
	Schneiderman et al., "Increased Type 1 Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries", <u>PNAS (USA)</u> , 89, 6998-7002 (1992).
	Schwartz et al., "Restenosis After Balloon Angioplasty -- A Practical Proliferative Model in Porcine Coronary Arteries", <u>Circulation</u> , 82, 2190-2200 (1990).
	Schwartz et al., "The Restenosis Paradigm Revisted: An Alternative Proposal for Cellular Mechanisms", <u>JACC</u> , 20, 1284-1293 (1992).
	Schwartz et al., "Maintenance of Integrity in Aortic Endothelium", <u>Federation Proceedings</u> , 39, 2618-2625 (1980).
	Shanahan et al., "High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plaques", <u>Journal of Clinical Investigation</u> , 93, 2393-2402 (1994).
	Shanahan et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells", <u>Circulation Research</u> , 73, 193-204 (1993).
	Serruys et al., "A Comparison of Balloon-Exandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", <u>The New England Journal of Medicine</u> , 331, 489-495 (1994).
	Serruys et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries - Early Outcome of hte Benestent-II Pilot Study", <u>Circulation</u> , 93, 413-422 (1996).
SB	Shoji et al., "Enhancement of Anti-Inflammatory Effects of Biphenyllylactic Acid by its Incorporation into Lipid Microspheres", <u>J. Pharm. Pharmacol.</u> , 38, 118-121 (1986).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)



\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Simpson et al., "Percutaneous Coronary Atherectomy", <u>Circulation</u> , 78, 61st Scientific Session, Abstract No. 0326, p. II-82 (1988).
	Snow et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", <u>American Journal of Pathology</u> , 137, 313-330 (1990).
	Sollott et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", <u>The Journal of Clinical Investigation</u> , 95, 1869-1876 (1995).
	Song, "Dexamethasine-nanoparticles for intra-arterial localization in restenosis in rats", <u>Proceec. Intern. Symp. Control. Rel. Mater.</u> , 22, 444-445 (1995).
	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", <u>Science</u> , 265, 391-394 (1994).
	Steele et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig Model", <u>Circulation Research</u> , 57, 105-112 (1985).
	Suckling, "Atherosclerosis Patents: Clues to the Next Drug Generation", <u>Bio/Technology</u> , 12, 1379-1380 (1994).
	Suckling, "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature", <u>Biochemical Society Transactions</u> , 21, 660-662 (1993).
	Tabas et al., "The Actin Cytoskeleton is Important for the Stimulation of Cholesterol Esterification by Atherogenic Lipoprotein in Macrophages", <u>The Journal of Biological Chemistry</u> , 269, 22547-22556 (1994).
	Tamm, "The Antibiotic Complex of the Verrucarins and Roridins", <u>Fortschr. Chem. Org. Naturst.</u> , 31, 61-117 (1973).
	Tanaka et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis by Vascular Smooth Muscle Cells.", <u>Atherosclerosis</u> , 107, 179-185 (1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SP	Tice et al., "Biodegradable controlled-release parental systems", <u>Pharmaceutical Technology</u> , 26-35, (November 1984).
	Topol et al., "The Restenosis "Antitheory"", <u>Mayo Clin. Proc.</u> , 68, 88-90 (1993).
	Vanhoutte, "Hypercholesterolaemia, Atherosclerosis and Release of Endothelium-Derived Relaxing Factor by Aggregating Platelets", <u>Eur. Heart J.</u> , 12, Suppl. E, 25-32 (1991).
	Vijayagopal et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor", <u>Biochemical Journal</u> , 289, 837-844 (1993).
	Vijayagopal et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation in Foam Cells from Rabbit Atherosclerotic Lesions", <u>J. Clin. Invest.</u> , 91, 1011-1018 (1993).
	Wei et al., "Binding of Trichodermin to Mammalian Ribosomes and Its Inhibition by Other 12,13-Epoxytrichothecenes", <u>Molecular &amp; Cellular Biochemistry</u> , 3, 215-219 (1974).
	Weissberg et al., "Approaches to the Development of Selective Inhibitors of Vascular Smooth Muscle Cell Proliferation", <u>Cardiovascular Research</u> , 27, 1191-1198 (1993).
	Weissberg et al., "Effects of TGF-Beta on Vascular Smooth Muscle Cell Growth", In: <u>Growth Factors and the Cardiovascular System</u> , Cummins, P., (ed.), Kluwer Academic Publishers, 189-205 (1993).
	Weissberg et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Co-mitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells", <u>Atherosclerosis</u> , 85, 257-262 (1990).
	Wight "Proteoglycans Structure and Function", <u>Cell Biol. of Extracellular Matrix, Second Edition</u> , E.D. Hay, Ed., Plenum Press, New York, 45-78, (1991).
SP	Wight et al., "Cell Biology of Arterial Proteoglycans.", <u>Arteriosclerosis</u> , 9, 1-20 (1989).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.007US4	Serial No. 09/590,002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: June 8, 2000	Group: 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SA	Wight et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", <u>Current Opinion in Cell Biol.</u> , 4, 793-801 (1992).
	Wilensky et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty", <u>American Heart Journal</u> , 122, 1136-1140 (1991).
	Wilensky, R.L., et al., "Regional and Arterial Localization of Radioactive Microparticles after Local Delivery by Unsupported or Supported Porous Balloon Catheters", <u>American Heart Journal</u> , 129, 852-859 (1995).
	Winslow, "Going for the Flow", <u>The Wall Street Journal</u> , (Oct. 23, 1995).
	Winternitz et al., "Development of a Polymeric Surgical Paste Formulation for Taxol", <u>Pharmaceutical Research</u> , 13, 368-375 (1996).
	Wolinsky et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery", <u>JACC</u> , 15, 475-481 (1990).
SA	Wright, et al., "Cytoclasin Inhibition of Slow Tension Increase in Rat Aortic Rings", <u>Am. J. Physiol.</u> , 267, H1437-H1446 (1994).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.